Business Wire

Appeals Court Confirms Conviction of Intercos Korea in Kolmar Korea Tech Theft

Share

Kolmar Korea (KRX: 161890) has won the victory in the remand trial against Intercos Korea, the Korean subsidiary of Italian cosmetics firm Intercos, concerning the misappropriation of its core sunscreen technology. The latest ruling has confirmed Intercos Korea is guilty of stealing Kolmar Korea’s technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113259255/en/

Kolmar Korea R&D Complex (photo: Kolmar Holdings)

The 3-2 Criminal Division of the Suwon District Court sentenced a fine of KRW 5 million on Intercos Korea for breaching the Unfair Competition Prevention and Trade Secret Protection Act on October 18. While the court reduced the fine from an initial KRW 10 million to KRW 5 million, it upheld the conviction of Intercos Korea. The ruling became final as Intercos Korea opted not to file an appeal.

Intercos Korea was alleged to have recruited “A”, a former Kolmar Korea employee, in order to acquire Kolmar’s sunscreen technology unlawfully. Joining Kolmar Korea since 2008, “A” had been in charge of research and development of sun care products. He suddenly resigned in 2018 due to immigration to the U.S. However, it was found that he joined Intercos Korea just one week after his departure. In the process, he reportedly leaked hundreds of Kolmar Korea's confidential documents via Google Drive.

Intercos Korea's sales of sun care products surged after “A” joined the company. Intercos Korea had no record of selling any UV protection products in 2017. However, it began selling sun care products after 2018 when “A” left Kolmar. The prosecution conducted a digital forensic analysis on the laptop used by "A", thereby uncovering evidence of his criminal activities.

In August 2021, the Suwon District Court sentenced “A” to ten months in prison. Additionally, “B”, an accomplice in the fraudulent activities, received a six-month sentence suspended for two years, and Intercos Korea was fined KRW 5 million. The appeal court reaffirmed the prison sentence for “A” and increased the fine for Intercos Korea to KRW 10 million.

“A” appealed the lower court’s decision, but the Supreme Court upheld the ten-month prison sentence, rendering the decision final. However, the Supreme Court found that the portion of the second trial decision imposing a KRW 10 million fine on Intercos Korea required further review and remanded it to the Suwon District Court. This decision was based on the Supreme Court’s finding that penalizing the company under joint penalty provisions for the "attempted" act of former employee “A” was unjustified.

In the subsequent retrial, the court recognized the harm suffered by Kolmar Korea. Although the fine against Intercos Korea was reduced due to the absence of legal grounds to penalize a juridical person for a “failed attempt”, the court maintained the conviction.

An official from Kolmar Korea said, "Intercos Korea is now proven guilty of misappropriating Kolmar Korea’s sun care technology. Hopefully, other Korean companies with world-class technologies will not face similar harm.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20241113259255/en/

Contacts

Kolmar Holdings
Jang-Woo Lee
jay.lee@kolmar.co.kr

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press Release

Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 100 points. TIME and Statista analyzed 3,000 major companies from 150 countries, focusing exclusively on those with trans

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press Release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press Release

ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors (corner cube prisms) designed to reflect laser beams directly back to their source, regardless of the an

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press Release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye